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Method
This was a multicentre retrospective study using micro-
costing methods to enable a precise assessment of the 
costs of MT from an NHS perspective. Data on resources 
used and their costs were collected from five UK 
neuroscience centres between 2015 and 2018.
Results
Data were collected on 310 patients with acute ischaemic 
stroke treated with MT. The mean total cost of providing 
MT and inpatient care within 24 hours was £10,846 (95% 
confidence interval (CI) 10,527–11,165) per patient. The main 
driver of cost was MT procedure costs, accounting for 73% 
(£7,943; 95% CI 7,649–8,237) of the total 24-hour cost. Costs 
were higher for patients treated under general anaesthesia 
(£11,048; standard deviation (SD) 2,654) than for local 
anaesthesia (£9,978; SD 2,654), mean difference £1,070 
(95% CI 381–1,759; p=0.003); admission to an intensive 
care unit (ICU; £12,212; SD 3,028) against for admission 
elsewhere (£10,179; SD 2,415), mean difference £2,032 (95% 
CI 1,345–2,719; p<0001).
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Introduction
The clinical efficacy and cost-effectiveness of mechanical 
thrombectomy (MT) for the treatment of large vessel occlusion 
stroke is well established, but uncertainty remains around the 
true cost of delivering this treatment within the NHS. The aim 
of this study was to establish the cost of providing MT within 
the hyperacute phase of care and to explore differences in 
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Methods
Study design
A multicentre retrospective cost analysis of stroke patients treated 
with MT with or without IVT was performed. A micro-costing 
approach was adopted from the perspective of the UK NHS, 
aiming to undertake the ‘direct enumeration and costing-out of 
every input consumed in the treatment of a particular patient’.11,12 
Such micro-costing data at the individual level can provide more 
precise estimates of costs and give insight into heterogeneity. The 
study was guided by economic principles and involved collection 
of detailed resource use information, notably the quantity and 
unit costs of all resources used along each individual patient’s 
treatment pathway (supplementary material S1). Data were 
collected on patients treated in line with routine clinical practice in 
five experienced and active thrombectomy centres.
Resource use data collection
The resources on which detailed information were collected 
included pre-hospital transportation; arrival at hospital, either 
to the emergency department, the radiology department 
or the stroke unit; imaging; procedural and staffing costs of 
thrombectomy; hospital or intensive care unit (ICU) stay after 
interventions; personnel hours; interventional radiology suite (IRS) 
or theatre usage; and type of anaesthesia used. Hospital stay up 
to 24 hours (ICU or stroke unit), inpatient care within 72 hours and 
overall duration of stay at the MT centre costs were determined.
Cost estimation
An NHS costing perspective was adopted and the cost per patient 
was measured and valued in pounds sterling at 2017–2018 
prices.13 Where unit costs were only available for previous years, a 
gross domestic product deflator was used to adjust.14 The average 
cost per hour of staff time in different categories was obtained 
from the Personal Social Services Research Unit (PSSRU).15 The cost 
of the individual thrombectomy device was obtained from each of 
the participating hospitals’ finance departments, as the national 
prices quoted by NICE have only been recently agreed. Other unit 
costs were collected from NHS healthcare resource group reference 
costs, NHS England specialised commissioning teams, individual 
participating hospitals’ finance departments, expert opinions and 
published data. The cost of alteplase for thrombolysis was taken 
from the British National Formulary.16 The results are presented 
in pounds sterling and converted to euros using 2018 World Bank 
purchasing power parity in supplementary material.17
Study sites
Five regional neuroscience centres in the UK participated in the 
micro-costing study. The centres were University Hospitals of 
North Midlands NHS Trust; Royal Victoria Hospital, Belfast; The 
Newcastle upon Tyne Hospitals NHS Foundation Trust; Queen 
Elizabeth Hospital Birmingham and University College London 
Hospitals NHS Foundation Trust. These are all neuroscience 
centres which provide MT both to local patients transferred directly 
(known as ‘mothership’) and to those initially transported to the 
nearest IVT centre and subsequently moved by secondary transfer 
to the neuroscience centre for MT (known as ‘drip-and-ship’). 
Additionally, in some regions, patients may be directly transferred 
The mean cost within 72 hours was £12,440 (95% CI  
10,628–14,252). The total costs for the duration of inpatient 
care before discharge from a thrombectomy centre was 
£14,362 (95% CI 13,603–15,122).
Conclusions
Major factors contributing to costs of MT for stroke include 
consumables and staff for intervention, use of general 
anaesthesia and ICU admissions. These findings can inform 
the reimbursement, provision and strategic planning of stroke 
services and aid future economic evaluations.




The total healthcare and societal costs of stroke to the NHS in 
England, Wales and Northern Ireland are estimated at £1.74 
billion at 1 year and £3.6 billion at 5 years after admission (mean 
cost per patient=£46,039).1 The clinical and cost effectiveness 
of mechanical thrombectomy (MT) with or without intravenous 
thrombolysis (IVT) for the treatment of large vessel occlusion 
stroke are both well established.2–6 Despite the evidence, detailed 
costs of delivering MT within most healthcare economies, 
including the UK NHS, remain unclear. Evidence on the main 
drivers of cost and its variability are also sparse.
Given the limited availability of thrombectomy centres and the 
ongoing restructuring of services, knowledge of the detailed costs 
of MT is essential for efficient resource allocation. In England, the 
current NHS tariff for providing MT is £11,750, but it is not clear 
how accurately this reflects routine clinical care or whether the 
tariff only covers the intervention, the hyperacute phase or the 
entire care pathway at the MT centre.7 The National Institute 
for Health and Care Excellence (NICE) has previously published 
prices for thrombectomy devices of two types, with ranges from 
£1,900 to £5,000 for stent-retrievers and from £550 to £1,349 
for thrombo-aspirators (per unit and excluding VAT).8 From the 
Sentinel Stroke National Audit Programme (SSNAP) data, in 
2018–19, of all the 87,635 acute ischaemic stroke (AIS) patients, 
1,200 (∼1.45%) were treated with MT in England, Wales and 
Northern Ireland.9 The number treated with MT is expected to 
rise as thrombectomy services evolve, particularly considering the 
ongoing plans for reorganisation and expansion of thrombectomy 
services.
Better evidence on the resources required and the real costs 
of providing MT in routine clinical settings would be invaluable 
not only to healthcare managers and commissioners, clinicians 
and researchers, but also to policy makers and planners in many 
European health systems. The need for more reliable and up-to-
date evidence is particularly acute in the UK, where the challenge 
is to improve access for the 10,000 UK stroke patients annually 
who could potentially benefit from MT.10
This study, therefore, aims to establish the cost of delivering MT 
in the clinical setting within the UK NHS (particularly within the 
hyperacute phase of care), to explore the resources used in care 
provision and to explore cost variations between the different 
models of care and across five treatment centres in the UK.
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to MT centres bypassing nearest IVT centre, before repatriation to 
their primary hospital (described as ‘direct transfer’ or ‘bypass’).
The direct transfer patients differ from the mothership patients 
because they are repatriated back to their local hospitals. Similarly, 
the direct transfer patients differ from the drip-and-ship patients, 
as they are taken first to MT centre for imaging, thrombolysis and 
thrombectomy before repatriation.
All patients included in the study across the five centres had 
moderate to severe ischaemic strokes (National Institutes of 
Health Stroke Scale (NIHSS) ≥6 for anterior circulation stroke and 
NIHSS <6 for basilar thrombus) treated with MT with or without 
IVT. Patients were treated in both mothership and drip-and-
ship models of care. Given the absence of direct patient contact 
and the retrospective collation and analysis of anonymised 
routinely collected data, no research ethics approval was required. 
Nonetheless, approval for participation was obtained from each 
hospital’s research and development department.
Statistical analysis
Data on resource quantities and unit costs of the different cost 
components were collected on a bespoke MS Excel spreadsheet. 
The populated spreadsheet was then exported to IBM SPSS 
version 25 to undertake descriptive and inferential statistical 
analyses.
The unit costs were presented as mean, standard deviation (SD) 
and 95% confidence interval (CI), median (range) for continuous 
variables, and with percentages for categorical variables. Mean 
cost differences were compared using Student’s t-tests. A p value 
of <0.05 was considered statistically significant.
Results
Patient characteristics and service configuration
Individual patient data were collected on 310 patients with AIS 
treated with MT with or without IVT from the five neuroscience 
centres treated between January 2015 and December 2018. 
One-hundred and ninety-two patients were treated in a mothership 
model and 118 in drip-and-ship. Among the mothership group, 
a small proportion of patients (n=26) were ‘bypass’ – directly 
transferred to MT centre before repatriation to primary hospital.
The median age of patients was 72 years (range 23–101);  
56 (18%) patients were >80 years old and 161 (52%) were male. 
The median baseline NIHSS score on admission was 17 (range 
3–35) and median 24-hour NIHSS was 9 (range 0–35). The median 
length of inpatient stay at the MT centre was 6 days (range 1–103) 
and for repatriated patients it was 4 days (range 1–72).
Costs
The mean total cost of providing MT and subsequent inpatient 
care over the first 24 hours was £10,846 (95% CI 10,527–11,165) 
per patient. The main cost driver was the thrombectomy 
procedure, which accounted for 73% (£7,943; 95% CI 
7,649–8,237) of the cost. The various components of costs are 
summarised in supplementary material S2, Table S1.
Costs were significantly higher for patients admitted to ICU 
straight after the procedure (£12,212; SD 3,028) than for those 
not admitted to ICU (£10,179; SD 2,415), mean difference £2,032 
(95% CI 1,345–2,719), p<0001. Similarly, patients with carotid 
stenosis who required carotid stenting and/or angioplasty during 
the thrombectomy procedure had higher costs (£12,474; SD 2,280) 
than those without additional stenting/angioplasty (£10,705; SD 
2,801), mean difference £1,768 (95% CI 795–2,741), p=0.001 
(supplementary material S2, Table S2).
The mean total cost of providing MT and subsequent inpatient 
care up to 72 hours of care was £12,440 (95% CI 10,628–14,252).
The total cost up to final discharge to all different destinations 
(home, community hospital, care home etc) from the MT centre 
was £14,362 (95% CI 13,603–15,122). The main driver of cost 
post-MT provision was ICU stay greater than 24 hours (£20,033; 
SD 11,130) compared with patients not admitted to ICU (£11,823; 
SD 3,510), mean difference £8,210 (95% CI 4,833–11,588);  
p<0001 (supplementary material S2, Table S2).
Subgroups
Different regions and centres
The 24-hour costs varied widely between centres, ranging from 
£8,858 (SD 1,727) to £12,942 (SD 3,246) with a significant mean 
difference of £4,084 (95% CI 5,087–3,080), p<0.001. The cost 
to discharge from the MT centre also varied widely, from £11,081 
(SD 4,245) to £18,889 (SD 5,047) with mean difference of £7,808 
(95% CI 9,583–6,033), p<0.001. The cost components per centre 
are summarised in supplementary material S2, Table S3.
Mothership vs drip-and-ship
For the 192 mothership patients, mean 24-hour costs of MT were 
£10,780 (SD 2,786) compared with £10,989 (SD 2,832) for the 118 
drip-and-ship patients, mean difference £209 (95% CI 453–870), 
p=0.54 in favour of mothership. There were statistically significant 
differences between mothership and drip-and-ship patients in 
transportation costs (£333 (SD 234) vs £568 (SD 258); mean 
difference £236 (95% Cl 178–293); p<0.001); in emergency 
hospital attendance costs (£532 (SD 94) vs £616 (SD 148); mean 
difference £85 (95% Cl 54–115); p<0.001); and imaging costs 
(£337 (SD 97) vs £485 (SD 223); mean difference £148 (95% 
Cl 104–192); p<0.001). The number of patients treated in the 
mothership vs drip-and-ship for each of the five centres are in 
supplementary material S2, Table S4.
Direct transfer or ‘bypass’ vs drip-and-ship
Among the 310 patients, only 26 were transferred directly to a 
thrombectomy centre before repatriation to primary hospital. 
The mean 24-hour cost of MT was £11,858 (SD 4,379) for 
direct transfer and £10,989 (SD 2,832) for drip-and-ship, mean 
difference £869 (95% CI 744–2743), p=0.36. The mean total 
cost until discharge from MT centre was £16,499 (SD 7,612) for 
direct transfer and £13,066 (SD 5,262) for drip-and-ship, mean 
difference £3,432 (95% Cl 90–6,775), p=0.45 in favour of drip-
and-ship. There was a statistically significant difference between 
direct transfer compared with drip-and-ship in imaging cost 
(£334 (SD 67) vs £485 (SD 223); mean difference £151 (95% 
Cl 102–200); p<0.001). No significant differences were found in 
costs of transportation, emergency hospital attendance (EHA) or 
procedure cost (supplementary material S2, Table S5).
Discussion
To our knowledge, this is the first multicentre comprehensive 
micro-costing study of MT treatment for AIS in Europe and the 
only study that captures the whole treatment pathway from 
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prehospital transportation through to hospital arrival, treatment 
and discharge from the MT centre. It is undertaken from the UK 
NHS perspective and provides a detailed insight into the true costs 
of providing MT in routine clinical care across five different centres. 
Our findings describe the cost of providing MT in a range of real-
world settings in a major western European healthcare economy.
Our estimated mean cost per patient of £10,846 (SD 2,796) 
within 24 hours post MT falls within the current NHS England 
tariff (reimbursement) of £11,750 (excluding market forces 
factor (MFF)) and the reimbursement of £12,000 for Northern 
Ireland, omitting any allowance for units and excluding potential 
additional costs related to ICU admission or carotid stenting.18 
However, the cost of care for the first 72 hours post-MT, especially 
for patients on ICU for more than 24 hours, is higher than the 
current NHS England tariff. The final reimbursement amount for 
each neuroscience centre varies depending on the MFF index for 
each region, which ranges from 1.025707 to 1.276880.19 It is also 
dependent on completion of the SSNAP database and activity 
being reported via Secondary Uses Service; however, it is unclear 
whether the reimbursement is only for the intervention or for the 
whole duration of stay at the MT centre.
Thrombectomy procedure costs accounted for three-quarters 
of the overall total thrombectomy cost in our study, particularly 
the cost within 24 hours. The main constituents of costs were 
thrombectomy devices; staffing; use of general anaesthesia with 
subsequent admission to ICU / high-dependency unit (HDU); and 
postoperative care. Patients treated with carotid stenting during 
the procedure also incurred higher costs.
A previous European economic analysis which used a micro-
costing approach but only included procedural costs, reported 
that the cost of the stent retriever (SR) and other consumables 
was £8,365.20 This was higher than the total of £7,943 (SD 2,631) 
identified by the current study. The previous (2015) study was also 
based on just one centre in the UK, while the current study covers 
multiple thrombectomy devices and involves five centres across 
different regions of the UK. In another single centre study by the 
same group in 2016, the procedural cost of MT was reported to be 
£7,283 including the costs of devices/consumables and staffing.21 
This was within the range of the current study but, again, only SR 
thrombectomy devices were costed.
A Swedish economic analysis was based on just 10 patients 
treated with MT from a single centre using predominately SR.22 
It reported MT costs comprising staff (neuro-interventionalist 
and neurologist), anaesthesia, surgery time, neurointensive care 
and MT devices (mainly SR) of £9,352. This was higher than 
the average £7,943 from the current study; however, the small 
sample size provided little insight into variability or heterogeneity 
or sources of difference in costs between patients or centres. In 
a Spanish cost analysis study, also using real-life resources, the 
cost of MT including predominantly SR devices with consumables 
and staffing was equivalent to £5,980.23 In a Norwegian health 
technology assessment, the estimated costs of MT including the 
procedure, diagnostical imaging and transport were estimated to 
be £5,919, substantially lower that the estimate in our study of 
these same components of £8,750.24 The higher MT costs in some 
of the economic analyses above compared with this current study, 
where a mixture of devices were used, could be related to the 
predominant use of SR devices for MT.
The study by Vega-Valdes et al, examining the cost of MT in 
Spain, was similar to our study in using retrospective individual 
patient data; however, it had a smaller sample size of 105 patients 
(44 patients treated with IVT and 61 with MT).25 Their estimated 
cost of MT was equivalent to £4,528 per patient, with an average 
final total cost of £12,070. The total figure covered the costs of 
emergency admission, imaging, physician consultation, admission 
up to 24 hours after intervention, rehabilitation sessions and 90-day 
outpatient follow-up. In contrast to the current study, they did not 
include costs across the whole treatment pathway, having excluded 
transportation and other periprocedural staff costs associated with 
MT. Overall, this study is more similar to our study than the other 
procedure-only studies; however, our study was not limited by a 
small sample and included all components of the care pathway.
In summary, past literature appears limited compared with 
the current study, which comprehensively includes resources and 
costs across the whole patient pathway including ambulance 
costs, the intervention, and hospital treatment to discharge. 
Differences in costs between the present study and previous 
studies could be due to a range of factors including variations in 
organisational set-up, geographical location, available resources, 
type of healthcare infrastructure, national and individual centre 
device costs (which can vary considerably), and type of models 
of care (mothership or drip-and ship); some of these are probably 
further impacted by currency exchange fluctuations.
Our study also provides new insights into variability across 
centres and between patient groups. The wide variation in the 
costs of providing MT across the centres arises mainly from a 
combination of differences in imaging costs (which are calculated 
differently in different hospitals, especially with regard to capital 
depreciation etc), relative use of SR (as opposed to other devices), 
relative use of general anaesthesia and the proportion of MT 
cases requiring ICU admission. Centres with higher use of general 
anaesthesia and ICU admission, in particular, had higher costs. 
This variation could also be partly explained by available resources 
and the way services are organised; patients may go straight 
to the stroke unit, or the radiology department bypassing the 
emergency department; repeat scans may occur for all drip-and-
ship patients or just for few selected cases; all facilities may be on 
one neuroscience site as opposed to two sites and immediate post-
MT imaging and 24-hour scans may be performed as opposed to 
only 24-hour post-MT scans. In addition, costs are not consistent 
between regions. In the London region, unit costs are uplifted 
by 13.9%, reflecting the much higher costs of healthcare inputs 
in the London conurbation than in most of the rest of the UK.26 
Therefore, organisational and cost variations can significantly 
affect the total cost of MT at each centre.
After the first 24 hours of care, the variation in costs arises from 
ICU admissions and subsequent length of stay, particularly for 
the drip-and-ship patients depending on whether there is a rapid 
repatriation policy for transfer back to referring primary hospital. 
Some of these variations could be reviewed in order to make the 
intervention more cost effective.
The main differences between the mothership and drip-and-ship 
service paradigm were mainly in costs associated with additional 
EHA and imaging costs, owing to repeat EHA and computed 
tomography at the MT centre. The significant difference in costs of 
transportation in the drip-and-ship group was due to inter-hospital 
transportation and repatriation costs. There were insufficient 
numbers to compare mothership and drip-and-ship separately for 
each of the five centres. The only significant difference between 
the direct transfer before repatriation and the drip-and-ship 
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models of care was primarily driven by the additional costs of 
repeat imaging.
The mothership and drip-and-ship are the commonly used 
models of care in most regions in the UK, particularly as identified 
in this study. The direct transfer model is not widely used but has 
become common in the London region since the reorganisation 
of stroke services there in 2010. The direct transfer model has 
been shown to reduce disability from stroke but, due to the small 
number of patients receiving that model of care in this study, 
further evidence on its costs is required particularly in regions 
outside London.27,28
Strengths and limitations
There were a number of strengths to our approach. Firstly, 
a bottom-up micro-costing approach was utilised. This 
allowed for the identification and quantification of resource 
use from pre-hospital transportation, arrival to hospital, 
imaging, intervention and hospital care until discharge from 
neuroscience centre as well as the costs component per 
individual patient, yielding better insight into drivers of costs, 
including within some patient subgroups. Additionally, the 
data were collected from patients treated in routine clinical 
practice which represented real-world data. Lastly, the fact that 
the data emanates from multiple centres in different regions, 
allows considerable potential for generalisation across wider 
healthcare economies where, as in the current study, differing 
referral pathways pertain (eg as regards proportionate use 
of mothership and drip-and-ship). Differing levels of brain 
imaging, general anaesthesia and of SR use may all apply 
between centres, regions and countries.
We also recognise some limitations to this study. Firstly, we 
were unable to collect further resource use or long-term outcome 
data after discharge from MT centres, particularly on patients 
repatriated back to their primary hospitals, or on those transferred 
for rehabilitation into the community. Rehabilitation costs and 
costs after repatriation up to discharge from primary hospitals are 
therefore not included and were outside the scope of the current 
study.
Secondly, the patients and centres included may not be fully 
representative of all MT patients across the UK, as less than the 
1.4% of patients from SNAPP were included.
Conclusion
We have provided detailed estimates of the current costs 
of providing MT in routine clinical settings from a UK NHS 
perspective. The main drivers of costs are the devices, use of 
general anaesthesia and admission to ICU/HDU. Our results 
should be valuable for all healthcare commissioners/funders 
and decision makers exploring the true cost of providing MT in 
a clinical setting. This will be particularly relevant in countries, 
such as the UK, where, for multiple reasons including the 
historical geographical location of centres (not optimum for MT 
provision) and shortfalls in required infrastructure and workforce 
manpower, there are limited numbers of thrombectomy centres. 
More generally, these findings should be of value for strategic 
planning/commissioning of stroke services, for future economic 
evaluations of interventions, and to inform future healthcare 
policy recommendations. ■
Supplementary material
Additional supplementary material may be found in the online 
version of this article at www.rcpjournals.org/clinmedicine:
S1 – Unit costs and references.
S2 – Costs breakdowns, comparisons and results.
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